Imagion reports results of cancer detection trials
Imagion Biosystems has presented new data indicating that its MagSense breast cancer imaging system ‘could help’ to discriminate between potentially cancerous and normal nodes in the body. Previously the company has only reported that its non-radioactive system was well tolerated and posed no safety issues in human trials. The Imagion’s system uses weak magnetic fields to detect MagSense nanoparticles coated with tumour targeting antibodies that can be administered by intravenous injection. The Melbourne company’s latest results were presented at a symposium in San Antonio.
Anagenics acquires skincare business
Anti ageing skincare company Anagenics has purchased the business of USPA skincare as it continues to pursue its strategy of growth through acquisition. The Sydney company paid an ‘immaterial’ sum for the spa and skincare business which it has represented as professional channel distributor. Anagenics said the acquisition’s IP and direct to consumer assets would provide broader revenue and margin benefits to the company. Anagenics sells its own and licenced brands of health and beauty products in Australia and internationally.
Picture University of Adelaide